Novo Nordisk, Deep Apple Therapeutics ink pact to develop oral therapeutics for Cardiometabolic Diseases

Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications. Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately prior to the start of IND-enabling studies.

Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.

"Novo Nordisk is a long-established global leader in delivering transformative treatments for cardiometabolic diseases, and the Deep Apple team is energized by the opportunity to collaborate with them," said Spiros Liras, Ph.D., CEO of Deep Apple and a venture partner at Apple Tree Partners (ATP). "This program highlights our platform capabilities in identifying potent, novel leads within months, and the partnership with Novo Nordisk will enable us to advance a first-in-class non-incretin program for cardiometabolic diseases."

"Novo Nordisk is developing a range of potential oral medicines for cardiometabolic diseases across modalities and targets, as we know that people living with these diseases have different needs and preferences," said Jacob Sten Petersen, Senior Vice President, Diabetes, Obesity and MASH therapeutic area at Novo Nordisk. "We look forward to exploring this novel target further based on Deep Apple's AI-powered platform and expertise in small molecule drug discovery."

The target is a non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple's platform, which captures the dynamics and motion of GPCRs and other proteins in different conformations to reveal novel pockets that can be docked with Deep Apple's proprietary virtual libraries.